A review of the metabolism of 1,4-butanediol diglycidyl ether-crosslinked hyaluronic acid dermal fillers

Dermatologic Surgery

Volumn 39, Issue 12, 2013, Pages 1758-1766

  De Boulle, Koenraad ^a   Glogau, Richard ^b   Kono, Taro ^c   Nathan, Myooran ^d   Tezel, Ahmet ^e   Roca Martinez, Jean Xavier ^f   Paliwal, Sumit ^e   Stroumpoulis, Dimitrios ^e  

^a Aalst Dermatology Group   (Belgium)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TOKAI UNIVERSITY   (Japan)

^d ALLERGAN PLC   (United States)

^e ALLERGAN INC   (United States)

^f Allergan France ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 4 BUTANEDIOL DIGLYCIDYL ETHER; 1,4 BUTANEDIOL; BIOMATERIAL; COSMETIC; EPOXIDE; FILLER; FREE RADICAL; GLYCEROL; HYALURONIC ACID; UNCLASSIFIED DRUG;

BIOACCUMULATION; BIOCOMPATIBILITY; CHEMICAL STRUCTURE; CITRIC ACID CYCLE; CROSS LINKING; DEGRADATION; DRUG METABOLISM; DRUG SAFETY; ENZYMATIC DEGRADATION; HUMAN; HYDROLYSIS; HYPERSENSITIVITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYNOVIAL FLUID; VISCOSUPPLEMENTATION;

ANIMALS; BIOCOMPATIBLE MATERIALS; BUTYLENE GLYCOLS; COSMETIC TECHNIQUES; CROSS-LINKING REAGENTS; GLYCEROL; HUMANS; HYALURONIC ACID; REJUVENATION; SKIN AGING; VISCOSUPPLEMENTS;

EID: 84889583244     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/dsu.12301     Document Type: Review

References (36)

1. Smith L, Cockerham K,. Hyaluronic acid dermal fillers: can adjunctive lidocaine improve patient satisfaction without decreasing efficacy or duration? Patient Prefer Adherence 2011; 5: 133-9.
2. ISAPS International Survey on Aesthetic/Cosmetic Procedures Performed in 2010. ISAPS, December 2011. Available from: http://www.isaps.org/files/html- contents/ISAPS-Procedures-Study-Results-2011.pdf Accessed January 2, 2013.
3. Afssaps Topical Report: Injectable products to fill wrinkles. Afssaps, June 2011. Available from: http://www.afssaps.fr/var/ansm-site/storage/original/ application/28d68bbb0f7ee427f4836b15cf107a1b.pdf Accessed January 2, 2013.
4. De Boulle K,. Management of complications after implantation of fillers. J Cosmet Dermatol 2004; 3: 2-15.
5. Radiesse Instructions for Use. Merz Aesthetics, Inc, October 2012 Available from: http://www.radiesse.com/en-US/downloads/RADIESSE-Wrinkle-Filler- Instructions-for-Use.pdf Accessed January 2, 2013.
6. Gold MH,. What's new in fillers in 2010? J Clin Aesthet Dermatol 2010; 3: 36-45.
7. Newman J,. Review of soft tissue augmentation in the face. Clin Cosmet Investig Dermatol 2009; 2: 141-50.
8. Kontis TC, Rivkin A,. The history of injectable facial fillers. Facial Plast Surg 2009; 25: 67-72.
9. Kim J-E, Sykes JM,. Hyaluronic acid fillers: history and overview. Facial Plast Surg 2011; 27: 523-8.
10. Stern R,. Hyaluronan catabolism: a new metabolic pathway. Eur J Cell Biol 2004; 83: 317-25. (Pubitemid 39307169)
11. Stern R, Kogan G, Jedrzejas M, Šoltés L,. The many ways to cleave hyaluronan. Biotechnol Adv 2007; 25: 537-57. (Pubitemid 47464847)
12. Fraser JRE, Laurent TE,. Turnover and metabolism of hyaluronan. In:, Evered D, Wheelan J, editors. The Biology of hyaluronan. Ciba Found Symp; 1989; 143: 41-59.
13. Volpi N, Schiller J, Stern R, Soltés L,. Role, metabolism, chemical modifications and applications of hyaluronan. Curr Med Chem 2009; 16: 1718-45.
14. Rees MD, Hawkins CL, Davies MJ,. Hypochlorite and superoxide radicals can act synergistically to induce fragmentation of hyaluronan and chondroitin sulphates. Biochem J 2004; 381: 175-84. (Pubitemid 38932223)
15. Alster TS, West T,. Effect of topical vitamin C on postoperative carbon dioxide laser resurfacing erythema. Dermatol Surg 1998; 24: 331-4. (Pubitemid 28150892)
16. Laurent UB, Dahl LB, Reed RK,. Catabolism of hyaluronan in rabbit skin takes place locally, in lymph nodes and liver. Exp Physiol 1991; 76: 695-703.
17. Engström-Laurent A, Hellström S,. The role of liver and kidneys in the removal of circulating hyaluronan an experimental study in the rat. Connect Tissue Res 1990; 24: 219-24.
18. Foureman P, Mason JM, Valencia R, Zimmering S,. Chemical mutagenesis testing in drosophila IX. Results of 50 coded compounds tested for the national toxicology program. Environ Mol Mutagen 1994; 23: 51-63. (Pubitemid 24125114)
19. Ciba-Geigy Corp. A cutaneous carcinogenicity study with mice on the diglycidyl ether of 1,4-butanediol. 1987.
20. Gerbal-Chaloin S,. Regulation de l'expression des cytochromes P450 de la sous-familler 2C dans des cultures primaires d'hépatocytes humains. Thèse Médecine: Université de Montpellier 1. Extrait. 2000.
21. INSERM. Généralités. In: Ethers de glycol-quels risques pour la santé? INSERM. ISBN 2-85598-761-X, ISSN 1264-1782: 1999. pp. 1-13
22. Métabolisme et toxicocinétique chez l'animal. In: Ethers de glycol-quels risques pour la santé? INSERM. ISBN 2-85598-761-X, ISSN 1264-1782: 1999. pp. 21-39
23. Ishikawa K,. 1,4-butanediol. OECD SIDS CAS N° 110-63-4 2000: 1-60.
24. NICNAS 1,4-butanediol. Existing chemical hazard assessment report ISBN 978-0-9803124-7-8 2009. pp. 1-25.
25. Irwin RD,. NTP summary report on the metabolism, disposition, and toxicity of 1,4-butanediol. National toxicology program toxicity report series (54) 1996. pp. 1-44.
26. Robertson S,. Glycerol. OECD SIDS CAS N° 56-81-5: 2002. pp. 1-178.
27. Pitlick WH, Pirikitakuhlr P, Painter MJ, Wessel HB,. Effect of glycerol and hyperosmolality on intracranial pressure. Clin Pharmacol Ther 1982; 31: 466-71. (Pubitemid 13097388)
28. Robergs RA, Griffin SE,. Glycerol: biochemistry, pharmacokinetics and clinical and practical applications. Sports Med 1998; 26: 145-67. (Pubitemid 28482704)
29. Frank MSB, Nahata MC, Hilty MD,. Glycerol: a review of its pharmacology, pharmacokinetics, adverse reactions, and clinical use. Pharmacotherapy 1981; 1: 147-60. (Pubitemid 12016089)
30. Larsen NE, Pollak CT, Reiner K, Leshchiner E, et al. Hylan gel biomaterial: dermal and immunologic compatibility. J Biomed Mater Res 1993; 27: 1129-34. (Pubitemid 23241076)
31. Jones D, Tezel A, Borrell M,. In vitro resistance to degradation of hyaluronic acid dermal fillers by ovine testicular hyaluronidase. Dermatol Surg 2010; 36: 804-9.
32. Sall I, Ferard G,. Comparison of the sensitivity of 11 crosslinked hyaluronic acid gels to bovine testis hyaluronidase. Polym Degrad Stab 2007; 92: 915-9. (Pubitemid 46654201)
33. Weiss C, Levy HJ, Denlinger JL, Suros JM, et al. The role of Na-hylan in reducing post-surgical tendon adhesions: Part I. Bull Hosp Jt Dis Orthop Inst 1986; 46: 9-15. (Pubitemid 16099112)
34. Weiss C, Suros JM, Michalow A, Moore M, et al. The role of Na-hylan in reducing post-surgical tendon adhesions Part II. Bull Hosp Jt Dis Orthop Inst 1987; 47: 31-9.
35. Malson T, Lindqvist BL,. Gel of crosslinked hyaluronic acid for use as a vitreous humor substitute. United States Patent n° 4 716 154 (1987)
36. Balazs EA, Denlinger JL,. Clinical uses of hyaluronan. Ciba Found Symp 1989; 143: 265-75.